Collplant Biotechnologies Ltd (CLGN) Stock Price, Chart & News

Earn 10$ Cash for every Pro+ Friend you Refer!

CLGN

3.91

USD-0.18-4.30%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Filings

News

Chart

Latest News

@eWhispers

1 year

#earnings before the open tomorrow https://t.co/lObOE0dgsr $KSS $ADI $XPEV $WOOF $ANF $BMO $BNS $LPG $EXPR $FUTU $DY $CLGN $SCVL $PLAB $KMDA $PLCE $ITRN $CRMT $BZ $ZH $BLRX $CRLBF $EXAI $PGRU $SGHC $LILM https://t.co/Nj6BmaCFYp

Analysts Recommendations

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

3.91USD

4.05USD

52 Week Range

3.31USD

6.99USD

Market Cap

46.8MUSD

About

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

IL0004960188

CUSIP

19516R107

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

December

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

2.48

Dividend Share

Dividend Yield

Earnings Share

-1.53

Wall Street Target Price

12.5

EPS Estimate Current Year

EPS Estimate Next Year

EPS Estimate Current Quarter

EPS Estimate Next Quarter

Most Recent Quarter

Profitability

Revenue TTM

689,000

Gross Profit TTM

13,636,000

EBITDA

-17,308,000

Profit Margin

0.00%

Return On Assets TTM

-33.77%

Return On Equity TTM

-61.55%

Revenue Per Share TTM

0.06

Qtly Revenue Growth YOY

-97.60%

Diluted Eps TTM

-1.53

Qtly Earnings Growth YOY

0.00%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

65.003

Price Book MRQ

2.7663

Enterprise Value Revenue

Enterprise Value EBITDA

-5

Peers analysis

CMXHFCSL Limited
178.29
4.66%
BNTXBioNTech SE
119.36
2.26%
VRTXVertex Pharmaceuticals Inc
472.25
0.57%
ALNYAlnylam Pharmaceuticals Inc
255.10
0.52%
BGNEBeiGene Ltd
188.00
0.27%

REGNRegeneron Pharmaceuticals Inc
778.55
0.01%
ARGNFargenx SE
525.60
0.00%
UCBJYUCB SA ADR
94.73
-1.46%
CSLLYCSL Ltd
89.92
-0.81%
ARGXargenx NV ADR
609.88
-0.50%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2024